When was Shgsmed.com founded?

Shgsmed.com was founded in 2019 and raised its 1st funding round 5 years after it was founded.

Is Shgsmed.com a funded company?

Shgsmed.com is a funded company, having raised a total of $***** in its 1st and only funding round, a Seed round on Nov 26, 2024.

When was the latest funding round of Shgsmed.com?

Shgsmed.com's latest funding was a $***** Seed round on Nov 26, 2024, with participation from 0 investor.

Where does Shgsmed.com rank among its competitors?

Shgsmed.com ranks 6th amongst 7 active competitors, only 1 of which is funded., of which only Shgsmed.com is funded and secured an undisclosed amount in Nov, 2024.

Who are the top competitors of Shgsmed.com?

Shgsmed.com's top competitors include IDRx, Draconis Pharma and Intima Bioscience. Among them, Shgsmed.com secured the most recent funding round in November, 2024.

Shgsmed.com - 2026 Company Profile, Funding & Competitors

Company Details

Developer of drugs for cancer treatment. It offers a lead compound sodium cypermethrin photodynamic therapy for the treatment of esophageal cancer with residual local disease or local reccurence after chemotherapy and radiotherapy.

Key Metrics

Founded Year

2019

Stage

Seed

Latest Funding Round

Seed, Nov 26, 2024, $*****

Ranked

6^th among 7 active competitors

Similar Companies

IDRx & 7 more

View Shgsmed.com's full profile

Shgsmed.com has raised funding over 1 round.

Here is the list of recent funding rounds of Shgsmed.com:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 26, 2024	6260335	Seed	7478205	4091450	4551839	8636110

Access funding benchmarks and valuations. Sign up today!

View details of Shgsmed.com's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Shgsmed.com include IDRx, Draconis Pharma and Intima Bioscience. Here is the list of Top 10 competitors of Shgsmed.com, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	IDRx 2022, Plymouth (United States), Acquired	Developer of precision combination therapies for cancer	$242M	Forge Life Science, RA Capital Management ... & 8 others	63/100
2nd	Draconis Pharma 2011, Barcelona (Spain), Funding Raised	Developer of therapeutic solutions for the treatment of therapies for the treatment of cancer, pain, & other diseases	-	Atiquity, TIBIDABO VENTURES	29/100
3rd	Intima Bioscience 2014, New York City (United States), Funding Raised	Developer of therapeutics to treat gastrointestinal cancer using CRISPR gene-editing technology	-	Morningside	25/100
4th	Checkmate Therapeutics 2019, Seoul (South Korea), Unfunded	Developer of therapeutics for cancer and neurological disorders	-	-	24/100
5th	Ganymed 2001, Mainz (Germany), Funding Raised	Developer of antibodies to treat cancer	-	Salvia	17/100
6th	Shgsmed.com 2019, Seed	Developer of drugs for cancer treatment	-	-	16/100
7th	Takeda Pharmaceuticals United States, Unfunded	Provider of pharmaceutical products focused on thoracic, gastrointestinal, and hematologic cancers	-	-	16/100
8th	Kupffer Biotherapeutics 2019, Burlingame (United States), Deadpooled	Developer of anticancer therapy for gastrointestinal cancer	-	-	15/100
9th	TLR Therapeutics 2022, Wilmington (United States), Deadpooled	Developer of therapeutics for the treatment of myelodysplastic syndrome and gastric cancer	-	Berkeley SkyDeck	14/100